1. Home
  2. VRAX vs ONFO Comparison

VRAX vs ONFO Comparison

Compare VRAX & ONFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • ONFO
  • Stock Information
  • Founded
  • VRAX 2013
  • ONFO 2018
  • Country
  • VRAX United Kingdom
  • ONFO United States
  • Employees
  • VRAX N/A
  • ONFO N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ONFO Computer Software: Programming Data Processing
  • Sector
  • VRAX Health Care
  • ONFO Technology
  • Exchange
  • VRAX Nasdaq
  • ONFO Nasdaq
  • Market Cap
  • VRAX 7.8M
  • ONFO 6.7M
  • IPO Year
  • VRAX 2022
  • ONFO 2022
  • Fundamental
  • Price
  • VRAX $2.37
  • ONFO $1.54
  • Analyst Decision
  • VRAX
  • ONFO
  • Analyst Count
  • VRAX 0
  • ONFO 0
  • Target Price
  • VRAX N/A
  • ONFO N/A
  • AVG Volume (30 Days)
  • VRAX 198.4K
  • ONFO 24.3K
  • Earning Date
  • VRAX 02-05-2025
  • ONFO 11-15-2024
  • Dividend Yield
  • VRAX N/A
  • ONFO N/A
  • EPS Growth
  • VRAX N/A
  • ONFO N/A
  • EPS
  • VRAX N/A
  • ONFO N/A
  • Revenue
  • VRAX $84,872.00
  • ONFO $6,590,171.00
  • Revenue This Year
  • VRAX $5,169.18
  • ONFO $133.59
  • Revenue Next Year
  • VRAX $66.97
  • ONFO N/A
  • P/E Ratio
  • VRAX N/A
  • ONFO N/A
  • Revenue Growth
  • VRAX 7.03
  • ONFO 29.25
  • 52 Week Low
  • VRAX $0.60
  • ONFO $0.39
  • 52 Week High
  • VRAX $9.00
  • ONFO $1.88
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 64.60
  • ONFO 58.02
  • Support Level
  • VRAX $1.51
  • ONFO $1.48
  • Resistance Level
  • VRAX $1.98
  • ONFO $1.60
  • Average True Range (ATR)
  • VRAX 0.18
  • ONFO 0.18
  • MACD
  • VRAX 0.03
  • ONFO -0.01
  • Stochastic Oscillator
  • VRAX 98.85
  • ONFO 48.95

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About ONFO Onfolio Holdings Inc.

Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.

Share on Social Networks: